Status:
COMPLETED
Study of Oral AEE788 in Adults With Advanced Cancer
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
AEE788 is an orally active, reversible, small-molecule, multi-targeted kinase inhibitor with potent inhibitory activity against ErbB and VEGF receptor family of tyrosine kinases. It has an IC50 of les...
Eligibility Criteria
Inclusion
- Histologically confirmed solid tumor
- Adequate hematologic, renal and hepatic function
- Age ≥ 18 years
- Karnofsky performance status score ≥ 70%
- Life expectancy ≥ 12 weeks
Exclusion
- Active brain metastases
- Peripheral neuropathy \> grade 2
- Diarrhea \> grade 1
- Gastrointestinal (GI) dysfunction
- Compromised cardiac function
- Concurrent severe and/or uncontrolled medical conditions
Key Trial Info
Start Date :
July 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
189 Patients enrolled
Trial Details
Trial ID
NCT00118456
Start Date
July 1 2003
Last Update
January 9 2012
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Yale Cancer Center
New Haven, Connecticut, United States, 06520
2
Nevada Cancer Institute
Las Vegas, Nevada, United States, 89125
3
Sarah Cannon Research Institute
Nashville, Tennessee, United States, 37203
4
MD Anderson Cancer Center
Houston, Texas, United States, 77054